Argitalpenak (210) CELIA OREJA GUEVARA argitalpenak

2024

  1. Clinical characteristics and impact on patient-reported outcomes and quality of life of people with ambulatory secondary progressive multiple sclerosis: Discover study

    Multiple Sclerosis and Related Disorders, Vol. 90

  2. Consensus statement of the Spanish Society of Neurology on the treatment of multiple sclerosis and holistic patient management in 2023

    Neurologia, Vol. 39, Núm. 2, pp. 196-208

  3. Defining a standard set of health outcomes for patients with relapsing-remitting multiple sclerosis

    Multiple Sclerosis and Related Disorders, Vol. 84

  4. Esclerosis múltiple y mujer

    Libro blanco salud y género (Estudio de comunicación), pp. 149-167

  5. Examining the environmental risk factors of progressive-onset and relapsing-onset multiple sclerosis: recruitment challenges, potential bias, and statistical strategies

    Journal of neurology, Vol. 271, Núm. 1, pp. 472-485

  6. Immediate and sustained terminal complement inhibition with ravulizumab in patients with anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder

    Frontiers in Neurology, Vol. 15

  7. Individual Prognostication of Disease Activity and Disability Worsening in Multiple Sclerosis With Retinal Layer Thickness z Scores

    Neurology: Neuroimmunology and NeuroInflammation, Vol. 11, Núm. 5

  8. Investigating the 2023 MOGAD Criteria in Children and Adults With MOG-Antibody Positivity Within and Outside Attacks

    Neurology, Vol. 103, Núm. 6

  9. Making Information About Cladribine Tablets Accessible to People with Multiple Sclerosis: A Patient-Survey-Led Narrative Review for Healthcare Professionals

    Neurology and Therapy, Vol. 13, Núm. 4, pp. 1015-1038

  10. Managing multiple sclerosis in individuals aged 55 and above: a comprehensive review

    Frontiers in Immunology, Vol. 15

  11. Sex ratio and age of onset in AQP4 antibody-associated NMOSD: a review and meta-analysis

    Journal of Neurology, Vol. 271, Núm. 8, pp. 4794-4812

2023

  1. A plain language summary of the impact of vaccines against flu and chickenpox in people with multiple sclerosis treated with cladribine tablets

    Neurodegenerative Disease Management, Vol. 13, Núm. 1, pp. 15-21

  2. Assisted Reproductive Techniques in Multiple Sclerosis: Recommendations from an Expert Panel

    Neurology and Therapy, Vol. 12, Núm. 2, pp. 427-439

  3. Development and usability testing of your MS questionnaire: A patient-based digital tool to monitor symptoms of multiple sclerosis

    Digital Health, Vol. 9

  4. Diagnosis and treatment of progressive multiple sclerosis: A position paper

    European Journal of Neurology, Vol. 30, Núm. 1, pp. 9-21

  5. ECTRIMS/EAN consensus on vaccination in people with multiple sclerosis: Improving immunization strategies in the era of highly active immunotherapeutic drugs

    Multiple Sclerosis Journal

  6. Early non-disabling relapses are important predictors of disability accumulation in people with relapsing-remitting multiple sclerosis

    Multiple sclerosis (Houndmills, Basingstoke, England), Vol. 29, Núm. 7, pp. 875-883

  7. European Committee for Treatment and Research in Multiple Sclerosis and European Academy of Neurology consensus on vaccination in people with multiple sclerosis: Improving immunization strategies in the era of highly active immunotherapeutic drugs

    European Journal of Neurology, Vol. 30, Núm. 8, pp. 2144-2176

  8. Expert opinion on COVID-19 vaccines and cladribine tablets in MS: A plain language summary

    Neurodegenerative Disease Management, Vol. 13, Núm. 1, pp. 5-13

  9. Expert opinion on the long-term use of cladribine tablets for multiple sclerosis: Systematic literature review of real-world evidence

    Multiple Sclerosis and Related Disorders, Vol. 69